Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Impact of intra‐tumoral immunity on predicting response and survival after neoadjuvant cisplatin‐based chemotherapy in patients with muscle invasive bladder cancer2024 · 4 citations
2. 2Prediction of platinum-based neoadjuvant chemotherapy response in muscle-invasive bladder cancer using a multifaceted approach2026
3. 3Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab2026
4. 4A phase II clinical trial of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible muscle invasive bladder cancer: The RAD VACCINE MIBC clinical trial.2026
5. 5Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancer2026 · 1 citations